Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of neuromuscular blocking agents (NMBA, e.g. rocuronium) on respiratory muscle activity is well known. However, since the availability of sugammadex, to our knowledge, no study has been conducted to evaluate the effect of this novel product on these muscles.

Our hypothesis is that by applying a different strategy in the use of neuromuscular blocking agents and their reversal agents we might see a different activity of the respiratory muscles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade

NCT02403063

Respiratory Muscles Electromyography

COMPLETED PHASE4

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

NCT03168308

Neuromuscular Blockade

COMPLETED PHASE4

The Use of Sugammadex in the Critically Ill

NCT03791801

Critical Illness

UNKNOWN NA

Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block

NCT05228223

Residual Neuromuscular Block Neuromuscular Blockade Monitoring

UNKNOWN NA

Functional Respiratory Imaging After Neostigmine or Sugammadex

NCT02284412

Respiratory-Gated Imaging Techniques

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diaphragmatic Dysfunction Muscle Weakness Muscle Fatigue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single rocuronium dose - placebo

The patients will receive a single rocuronium dose, and no reversal agent.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Single rocuronium dose

Intervention Type DRUG

Single rocuronium dose - sugammadex

The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent

Group Type ACTIVE_COMPARATOR

sugammadex 2mg/kg

Intervention Type DRUG

Single rocuronium dose

Intervention Type DRUG

Repeated rocuronium dose - neostigmine

The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent

Group Type ACTIVE_COMPARATOR

neostigmine

Intervention Type DRUG

Repeated rocuronium dose

Intervention Type DRUG

Repeated rocuronium dose - sugammadex

The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent

Group Type ACTIVE_COMPARATOR

sugammadex 2mg/kg

Intervention Type DRUG

Repeated rocuronium dose

Intervention Type DRUG

Continuous rocuronium dose

The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent

Group Type ACTIVE_COMPARATOR

sugammadex 4mg/kg

Intervention Type DRUG

Continuous rocuronium infusion

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sugammadex 2mg/kg

Intervention Type DRUG

neostigmine

Intervention Type DRUG

sugammadex 4mg/kg

Intervention Type DRUG

placebo

Intervention Type DRUG

Single rocuronium dose

Intervention Type DRUG

Repeated rocuronium dose

Intervention Type DRUG

Continuous rocuronium infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Each participant must have the mental capacity to decide whether he/she takes part in the trial or not. Each participant must voluntarily give his/her written informed consent. In case a participant is physically unable to give a written informed consent, a legal representative is to perform this.
* Each participant must be at least eighteen years of age. Participants can be of either sex and of any ethnical background.
* Each participant must meet the American Society of Anesthesiologists class II, II or III criteria.
* Each participant must be scheduled for intracranial surgery. During general anesthesia rocuronium must be used as a neuromuscular blocking agent.
* Each participant must be a suitable candidate for the rapid reversal of the neuromuscular blockade.
* Each female participant of sexually active age and of childbearing potential must agree to the use of a medically accepted method of contraception through seven days after the day of surgery. Postmenopausal (defined as at least twelve consecutive months without spontaneous menstrual period) women are not obliged to use contraceptives.

Exclusion Criteria

* The participant is known or suspected to have a neuromuscular disorder.
* The participant is known or suspected to have an allergic reaction to sugammadex, rocuronium, anesthetic or narcotic medications, or any drugs used during general anesthesia.
* The participant is known or suspected to have an anatomical malformation impeding a proper intubation.
* The participant is known or suspected to have a history of malignant hyperthermia.
* The participant is pregnant (or intends to become pregnant within the presurgical period) or lactating.
* The participant is known to have a renal insufficiency (defined as a serum creatinine concentration of two times the upper limit, or a glomerular filtration rate of less than 60 ml/min).
* The participant is known or suspected to have a chronic obstructive pulmonary disease GOLD classification 2 or higher or has any respiratory disease that impairs his respiratory function to a NYHA III level or worse.
* The participant is known to have an infection of the upper or lower airways, as diagnosed by clinical or laboratory findings.
* The participant is known or suspected to have congestive heart failure.
* The participant is obese, as defined by a body mass index of 30 kg/m2 or more.
* The participant is known or suspected to have a major hepatic dysfunction.
* The participant has received or is scheduled to receive toremifene and/or an intravenous administration of fusidic acid within a time span of twenty-four hours before and twenty-four hours after the surgery.
* The participant is known or suspected to have any condition contraindicating the administration of sugammadex, neostigmine, glycopyrrolate or placebo.
* The participant is known or suspected to be directly involved in this study and/or is employed by or is a family member of any person employed by the investigator, at the investigational site, or by the sponsor.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No